UK's Oxford Nanopore prelim 2025 revenue rises 22.2% on broad-based growth

Oxford Nanopore Technologies

02/03/2026 07:10

Overview

Molecular sensing firm's prelim 2025 revenue grew 22.2%

Adjusted EBITDA loss narrowed, driven by improved operational performance

Company reaffirmed commitment to reach adjusted EBITDA breakeven in FY27

Outlook

Oxford Nanopore expects FY26 revenue growth of 21-25% on constant currency basis

Company anticipates FY26 gross margin of approximately 62%

Oxford Nanopore reaffirms adjusted EBITDA breakeven in FY27

Result Drivers

BROAD-BASED GROWTH - Revenue growth driven by demand across all regions, products, and customer types

PRODUCT RANGE EXPANSION - PromethION product range saw fastest growth at 43.1% year-on-year

MARGIN IMPROVEMENTS - Gross margin increased due to new pricing model and operational efficiencies

Company press release: ID:nRSB8911Ua

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Revenue
GBP 223.90 mln
FY Net Income
-GBP 145.20 mln
FY Adjusted EBITDA
-GBP 86.70 mln
FY Gross Margin
58.60%
FY Gross Profit
GBP 131.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Oxford Nanopore Technologies PLC is GBp200.00, about 50.3% above its February 27 closing price of GBp133.10

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)